Skip to main content
. 2018 Apr 24;9(31):21674–21686. doi: 10.18632/oncotarget.24670

Figure 3. Pharmacodynamic (PD) kinetics study for the combination of selumetinib and DTIC in the MP55 UM PDX.

Figure 3

(A) Evaluation of normalized MAPK protein levels (MEK, p-MEK, ERK, p-ERK) at three different time points after selumetinib, DTIC, or selumetinib + DTIC administration in vivo. (B) Evaluation of normalized Pi3K protein levels (AKT, p-AKT, S6, p-S6) at three different time points after selumetinib, DTIC, or selumetinib + DTIC administration in vivo. (C) Western blot of MAPK proteins (MEK, p-MEK, ERK, p-ERK) at three different time points after selumetinib, DTIC, or selumetinib + DTIC administration in vivo. (D) Western blot of normalized Pi3K protein levels (AKT, p-AKT, S6, p-S6) at three different time points after selumetinib, DTIC, or selumetinib + DTIC administration in vivo.